Aston Sci. Inc.
- Biotech or pharma, therapeutic R&D
Aston Sci Inc. is seeking opportunity in the following area:
. licensing out of the AST-301 (phase 2, HER2 vaccine for gastric cancer) and AST-201 (phase 2 approved, IGFBP-2 ovarian cancer vaccine) or opportunity to combine with late stage ADC of these assets
. collaboration for the discovery of mRNA/LNP cancer or anti-inflammatory assets
. Business opportunity for the GCN2 asset for the cnacer metabolism/ sickle cell disease
. Business opportunity for the epilepsy project (NFkB inhibitor, in-vivo (PTZ) proven for the inhibition of the kindling of the epielpsy
We do support MetiMedi Pharm:
. MetMedi 101: EGFR and SRC degrader for Cetuximab resistant mCRC patient
. UV sunscreen booster with neo in-organic booster
We also do support Korea Research Institute of BioScience and BioTechnology (KRIBB)
. business opportuntiy for the regenerative medicine for the rejuvenation: New factor other than OSKM
in-vivo rejuvenation is confirmed.
Please no meeting request from consulting company or CMO/CDMO
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}